
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Enabling adolescents with chronic pulmonary disease to exercise or play sports regularly can improve their health. The keys are to arrive at the proper diagnosis, prescribe the right treatment, and recommend the most appropriate activity.






